Haystack Oncology, Inc. Sustainability Profile
Haystack Oncology, Inc., a pioneering force in the biotechnology sector, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in the development of innovative cancer diagnostics and therapeutics. Haystack Oncology focuses on utilising advanced genomic technologies to enhance precision medicine, particularly in the realm of oncology. The company’s flagship products include cutting-edge liquid biopsy tests that enable early cancer detection and monitoring, setting them apart in a competitive market. With a commitment to improving patient outcomes, Haystack Oncology has achieved significant milestones, including collaborations with leading research institutions. Their unique approach to cancer care positions them as a notable player in the industry, dedicated to transforming the landscape of cancer treatment through science and innovation.
DitchCarbon Score
How does Haystack Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haystack Oncology, Inc.'s score of 31 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Haystack Oncology, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Quest Diagnostics Incorporated, which provides emissions data that may be relevant to Haystack's climate commitments. As of now, there are no documented reduction targets or climate pledges specific to Haystack Oncology. The absence of direct emissions data suggests that the company may rely on the sustainability initiatives and performance metrics of its parent organisation, Quest Diagnostics. This relationship indicates that any climate commitments or emissions reductions may be influenced by the broader corporate strategies of Quest Diagnostics. In the context of the industry, it is essential for companies like Haystack Oncology to align with established climate frameworks and targets, such as those set by the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific initiatives or targets have not been disclosed for Haystack Oncology at this time. Overall, while direct emissions data and reduction commitments are not available, the company's affiliation with Quest Diagnostics may provide a pathway for future climate action and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 83,929,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 145,724,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 41,299,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Haystack Oncology, Inc.'s Industry?
How Carbon Intensive is Haystack Oncology, Inc.'s Location?
Haystack Oncology, Inc.'s Scope 3 Categories Breakdown
Haystack Oncology, Inc.'s Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
Haystack Oncology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Haystack Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.